Hemogenyx Pharmaceuticals PLC Presentation at Cancer Immunotherapy Conference (4516O)

TIDMHEMO

RNS Number : 4516O

Hemogenyx Pharmaceuticals PLC

30 January 2019

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Hemogenyx to Present at the 'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit' conference

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that its CEO Dr Vladislav Sandler will present at the conference 'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit'. The conference is taking place in Whistler, Canada from 10 to 14 March 2019 and is organized within the Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/Egxj3V).

Dr Sandler's presentation is entitled 'A Novel Anti-FLT3-CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia and Conditioning of Patients for Hematopoietic Stem Cell Transplantation'. The presentation will highlight the fact that, despite numerous advances in understanding the biology and pathogenesis of acute myeloid leukemia (AML), treatment remains unsatisfactory and that relapsed or refractory AML is nearly universally fatal. The presentation will describe the state of development of the Company's CDX antibodies and their potential benefit for the treatment of AML and conditioning of patients for hematopoietic stem cell (HSC) transplantation.

Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/epxTuf) is a nonprofit organization with a 47-year history of convening open, peer-reviewed conferences that connect the scientific community and accelerate life science discovery. Its Scientific Advisory Board is comprised of eminent biomedical scientists whose expertise derives from academia, industry, and the government (https://goo.gl/GtwUjT).

Enquiries:

 
 Hemogenyx Pharmaceuticals plc                                                   www.hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive                                             Via Walbrook PR 
  Officer & Co-Founder 
 Sir Marc Feldmann, Executive Chairman 
 
 Northland Capital Partners Limited                                       Tel: [phone] 
 Matthew Johnson, Vadim Alexandre 
 
 Peterhouse Corporate Finance Limited                                     Tel: [phone] 
 Lucy Williams, Duncan Vasey 
 
 Walbrook PR (UK Media & Investor Relations)                           Tel: [phone] or 
                                                                          [e-mail] 
 Paul McManus                                                             Mob: [phone] 
 
 US Media enquiries 
 Lowell Goodman                                Tel: [phone] or [e-mail] 
 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in New York City at its state-of-the-art research facility ("Hemogenyx").

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCMMGZMVLGGLZM

(END) Dow Jones Newswires

January 30, 2019 02:00 ET (07:00 GMT)